Physician profile
Laura Staff
NPI 1174521363
$6,678.56
in general payments reported to CMS, 2019-2025
17 companies · $1,585 in 2025
The $1,585 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $291 · 2020: $85.70 · 2021: $1,001 · 2022: $962 · 2023: $1,499 · 2024: $1,255 · 2025: $1,585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,339.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,338.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,712.39 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $828.33 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbott Laboratories | $659.98 | 2021-2025 | Freestyle Libre 3 |
| Grifols USA, LLC | $493.64 | 2022-2024 | Xembify, Gamunex-C |
| Lilly USA, LLC | $396.55 | 2019-2025 | Mounjaro, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $292.35 | 2019-2021 | |
| Axsome Therapeutics, INC. | $254.68 | 2025 | Auvelity |
| Gilead Sciences, INC. | $246.60 | 2023-2024 | Descovy |
| W. L. Gore & Associates, INC. | $138.24 | 2024 | Gore Cardioform Septal Occluder |
| Glaxosmithkline, LLC. | $130.28 | 2023-2024 | Bexsero |
| Abbvie INC. | $126.55 | 2021 | |
| Phathom Pharmaceuticals, INC. | $125.00 | 2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.92 | 2025 | Jardiance |
| Pfizer INC. | $62.65 | 2024 | |
| Hologic Sales and Service, LLC | $39.81 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $31.93 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.66 | 2023 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Staff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.